Literature DB >> 31577512

Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems.

Simon P Wells1,2, Helen M Waddell1, Choon Boon Sim3, Shiang Y Lim4,5, Gabriel B Bernasochi1, Davor Pavlovic2, Paulus Kirchhof2,6, Enzo R Porrello1,3, Lea M D Delbridge1, James R Bell1,7.   

Abstract

Cardiac arrhythmias of both atrial and ventricular origin are an important feature of cardiovascular disease. Novel antiarrhythmic therapies are required to overcome current drug limitations related to effectiveness and pro-arrhythmia risk in some contexts. Cardiomyocyte culture models provide a high-throughput platform for screening antiarrhythmic compounds, but comparative information about electrophysiological properties of commonly used types of cardiomyocyte preparations is lacking. Standardization of cultured cardiomyocyte microelectrode array (MEA) experimentation is required for its application as a high-throughput platform for antiarrhythmic drug development. The aim of this study was to directly compare the electrophysiological properties and responses to isoproterenol of three commonly used cardiac cultures. Neonatal rat ventricular myocytes (NRVMs), immortalized atrial HL-1 cells, and custom-generated human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured on microelectrode arrays for 48-120 h. Extracellular field potentials were recorded, and conduction velocity was mapped in the presence/absence of the β-adrenoceptor agonist isoproterenol (1 µM). Field potential amplitude and conduction velocity were greatest in NRVMs and did not differ in cardiomyocytes isolated from male/female hearts. Both NRVMs and hiPSC-CMs exhibited longer field potential durations with rate dependence and were responsive to isoproterenol. In contrast, HL-1 cells exhibited slower conduction and shorter field potential durations and did not respond to 1 µM isoproterenol. This is the first study to compare the intrinsic electrophysiologic properties of cultured cardiomyocyte preparations commonly used for in vitro electrophysiology assessment. These findings offer important comparative data to inform methodological approaches in the use of MEA and other techniques relating to cardiomyocyte functional screening investigations of particular relevance to arrhythmogenesis.

Entities:  

Keywords:  HL-1 cells; cardiomyocyte electrophysiology; human iPS-derived cardiomyocytes; microelectrode array; neonatal rat ventricular myocytes

Mesh:

Substances:

Year:  2019        PMID: 31577512      PMCID: PMC6962518          DOI: 10.1152/ajpcell.00306.2019

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  47 in total

1.  Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes.

Authors:  G Meiry; Y Reisner; Y Feld; S Goldberg; M Rosen; N Ziv; O Binah
Journal:  J Cardiovasc Electrophysiol       Date:  2001-11

2.  Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model.

Authors:  Thomas J Hund; Yoram Rudy
Journal:  Circulation       Date:  2004-10-25       Impact factor: 29.690

3.  A method for genetic modification of human embryonic stem cells using electroporation.

Authors:  Magdaline Costa; Mirella Dottori; Koula Sourris; Pegah Jamshidi; Tanya Hatzistavrou; Richard Davis; Lisa Azzola; Steven Jackson; Sue Mei Lim; Martin Pera; Andrew G Elefanty; Edouard G Stanley
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte.

Authors:  W C Claycomb; N A Lanson; B S Stallworth; D B Egeland; J B Delcarpio; A Bahinski; N J Izzo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

5.  Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.

Authors:  Sonia Goineau; Vincent Castagné
Journal:  J Pharmacol Toxicol Methods       Date:  2017-12-20       Impact factor: 1.950

6.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

Review 7.  Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview.

Authors:  Christine L Mummery; Jianhua Zhang; Elizabeth S Ng; David A Elliott; Andrew G Elefanty; Timothy J Kamp
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

8.  Sex and strain differences in adult mouse cardiac repolarization: importance of androgens.

Authors:  Judith Brouillette; Katy Rivard; Eric Lizotte; Céline Fiset
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

9.  Electrical Stimulation Promotes Cardiac Differentiation of Human Induced Pluripotent Stem Cells.

Authors:  Damián Hernández; Rodney Millard; Priyadharshini Sivakumaran; Raymond C B Wong; Duncan E Crombie; Alex W Hewitt; Helena Liang; Sandy S C Hung; Alice Pébay; Robert K Shepherd; Gregory J Dusting; Shiang Y Lim
Journal:  Stem Cells Int       Date:  2015-12-14       Impact factor: 5.443

10.  Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care.

Authors:  Deirdre A Lane; Flemming Skjøth; Gregory Y H Lip; Torben B Larsen; Dipak Kotecha
Journal:  J Am Heart Assoc       Date:  2017-04-28       Impact factor: 5.501

View more
  5 in total

1.  An American Physiological Society cross-journal Call for Papers on "Deconstructing Organs: Single-Cell Analyses, Decellularized Organs, Organoids, and Organ-on-a-Chip Models".

Authors:  Josephine C Adams; P Darwin Bell; Sue C Bodine; Heddwen L Brooks; Nigel Bunnett; Bina Joe; Kara Hansell Keehan; Thomas R Kleyman; André Marette; Rory E Morty; Jan-Marino Ramírez; Morten B Thomsen; Bill J Yates; Irving H Zucker
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-01       Impact factor: 5.464

Review 2.  Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.

Authors:  Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

3.  Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokine-Mediated Inhibition of Connexin43 Expression.

Authors:  Pietro Enea Lazzerini; Maurizio Acampa; Michael Cupelli; Alessandra Gamberucci; Ujala Srivastava; Claudio Nanni; Iacopo Bertolozzi; Francesca Vanni; Alessandro Frosali; Anna Cantore; Alessandra Cartocci; Antonio D'Errico; Viola Salvini; Riccardo Accioli; Decoroso Verrengia; Fabio Salvadori; Aleksander Dokollari; Massimo Maccherini; Nabil El-Sherif; Franco Laghi-Pasini; Pier Leopoldo Capecchi; Mohamed Boutjdir
Journal:  J Am Heart Assoc       Date:  2021-10-29       Impact factor: 5.501

4.  An improved procedure for isolating adult mouse cardiomyocytes for epicardial activation mapping.

Authors:  Ziguan Zhang; Wuyang Zheng; Dehua He; Zichao Hu; Qiang Xie; Meirong Huang; Weihua Li; Zhengrong Huang
Journal:  J Cell Mol Med       Date:  2021-11-10       Impact factor: 5.310

Review 5.  Basic Research Approaches to Evaluate Cardiac Arrhythmia in Heart Failure and Beyond.

Authors:  Max J Cumberland; Leto L Riebel; Ashwin Roy; Christopher O'Shea; Andrew P Holmes; Chris Denning; Paulus Kirchhof; Blanca Rodriguez; Katja Gehmlich
Journal:  Front Physiol       Date:  2022-02-07       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.